Lilly’s Retevmo receives FDA approval to treat solid tumours
Retevmo (selpercatinib, 40 mg & 80 mg capsules) is indicated to treat locally advanced or metastatic solid tumours in adult patients with a rearranged during transfection (RET) gene
NewcelX has signed a collaborative research agreement with Eledon Pharmaceuticals to advance its NCEL-101 programme for type 1 diabetes (T1D).